Cannot be asked to compensate for deaths due to Covid-19 vaccines: Centre

The government cannot be held liable to compensate for the deaths due to an adverse event following immunisation (AEFI) post administration of Covid-19 vaccines, the Centre has told the Supreme Court

Coronavirus vaccines, booster shot
Photo: Bloomberg
Press Trust of India New Delhi
3 min read Last Updated : Nov 29 2022 | 11:22 PM IST

Don't want to miss the best from Business Standard?

The government cannot be held liable to compensate for the deaths due to an adverse event following immunisation (AEFI) post administration of Covid-19 vaccines, the Centre has told the Supreme Court.

The affidavit filed in the apex court by the Centre assumes significance in view of the fact that the government has been zealously pursuing the Covid-19 vaccination programme to fight the pandemic and, as per latest reports, over 219 crore doses have been administered.

The affidavit was filed in response to a petition by the parents of two girls who died allegedly due to adverse effects following Covid vaccination.

It claimed vaccines manufactured by third parties had successfully undergone regulatory review, and holding the state directly liable to provide compensation may not be legally sustainable.

"The vaccines in use under the vaccination program are manufactured by third parties and have successfully undergone thorough regulatory review in India as well as other nations, being recognised globally as safe and effective," it said.

"In these facts, it is most humbly submitted that holding the State directly liable to provide compensation under the narrow scope of strict liability for extremely rare deaths occurring due to AEFIs from the use of vaccines may not be legally sustainable," the affidavit said.

It said the Centre has made substantial efforts in ensuring a safe and effective vaccination programme against COVID-19 in the middle of a highly challenging situation presented by the pandemic.

The affidavit, filed by the Ministry of Health and Family Welfare (MoHFW), said there was no material to suggest how the State can be fastened with strict liability to compensate.

It added there was no legal compulsion to obtain vaccination and that it was purely voluntary.

"The concept of informed consent is inapplicable to the voluntary use of a drug such as a vaccine. While the Government of India strongly encourages all eligible persons to undertake vaccination in public interest, there is no legal compulsion for the same," it said.

The Centre further added that all relevant information on COVID-19 vaccination was made freely available in public domain by both the vaccine manufacturers and MoHFW and that the petitioners were free to access more information on their own about possible adverse effects of a vaccine.

"As such, once a vaccine beneficiary who has access to all relevant information, voluntarily chooses to enter a vaccination center and receive vaccination, the question of a lack of informed consent does not arise," the affidavit said.

The daughters of the petitioners were aged 19 and 20 years.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Coronavirus VaccineSupreme CourtCentre

First Published: Nov 29 2022 | 11:22 PM IST

Next Story